Huarun 999 Independent Director Sun Jian Released 2025 Annual Duty Fulfillment Report, Focusing on Related Party Transactions and Major Reorganizations

China Visitor Network Data: Independent Director Sun Jian of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. recently released the 2025 annual performance report, detailing his duties. The report shows that in 2025, Sun Jian personally attended all 15 board meetings and 8 shareholder meetings, and as chairman of the Audit Committee, presided over 6 Audit Committee meetings. During his tenure, Sun Jian focused on several major company matters, including reviewing and approving related-party transactions such as cooperation with China Resources Power New Energy Project, the expected routine related-party transactions for 2026, and the renewal of energy procurement agreements with subsidiaries. The total estimated transaction amount exceeded 5 billion yuan. The report also mentions ongoing attention and review of the company’s major asset restructuring involving the acquisition of Tasly Pharmaceutical Group Co., Ltd. The independent director special meeting believed this transaction benefits the company’s long-term development, is fairly priced, and has urged relevant parties to provide commitments regarding potential industry competition and related-party transaction issues.

In financial supervision, Sun Jian maintained communication with internal audit agencies and annual auditors, approving the re-engagement of KPMG Huazhen Certified Public Accountants as the company’s 2025 audit firm, the 2024 profit distribution plan (distributing 3.2 yuan per 10 shares and transferring 3 shares), and the 2025 semi-annual profit distribution plan (distributing 4.5 yuan per 10 shares). The report also covers adjustments, unlockings, and repurchase cancellations related to the company’s 2021 restricted stock incentive plan, where approximately 4.7479 million restricted shares were repurchased and canceled due to unmet performance conditions in the third unlocking period.

Sun Jian stated in the report that during his tenure, he actively used his professional knowledge to make independent judgments, effectively safeguarding the interests of the company and minority shareholders, and he expressed recognition of the company’s efficient progress in the acquisition and integration of Tasly.